Choline phosphate cytidylyltransferase-α is a novel antigen detected by the anti-ERCC1 antibody 8F1 with biomarker value in patients with lung and head and neck squamous cell carcinomas

Cancer

Volumn 120, Issue 12, 2014, Pages 1898-1907

  Vaezi, Alec E ^a,c   Bepler, Gerold ^b   Bhagwat, Nikhil R ^a,c   Malysa, Agnes ^b   Rubatt, Jennifer M ^a,c   Chen, Wei ^b   Hood, Brian L ^a,c   Conrads, Thomas P ^a,c   Wang, Lin ^a   Kemp, Carolyn E ^c   Niedernhofer, Laura J ^a,c,d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d Scripps Institute   (United States)

Author keywords

choline phosphate cytidylyltransferase (CCT ); ERCC1; head and neck cancer; lung cancer

Indexed keywords

BIOLOGICAL MARKER; CHOLINE PHOSPHATE CYTIDYLYLTRANSFERASE; CHOLINE PHOSPHATE CYTIDYLYLTRANSFERASE ALPHA; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1 ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY SPECIFICITY; ANTIGEN DETECTION; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; CROSS REACTION; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CHOLINE PHOSPHATE CYTIDYLYLTRANSFERASE-Α (CCTΑ); ERCC1; HEAD AND NECK CANCER; LUNG CANCER;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CHOLINE-PHOSPHATE CYTIDYLYLTRANSFERASE; COHORT STUDIES; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84902184512     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28643     Document Type: Article

References (33)

1. Vaezi A, Feldman CH, Niedernhofer L,. ERCC1 and XRCC1 as biomarkers for lung and head and neck cancer. Pharmacogenomics Pers Med. 2011; 4: 47-63.
2. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006; 355: 983-991.
3. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G,. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med. 2007; 356: 800-808.
4. Reynolds C, Obasaju C, Schell MJ, et al. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol. 2009; 27: 5808-5815.
5. Jiang J, Liang X, Zhou X, Huang R, Chu Z, Zhan Q,. ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis. Mol Biol Rep. 2012; 39: 6933-6942.
6. Roth JA, Carlson JJ,. Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis. Clin Lung Cancer. 2011; 12: 393-401.
7. Chen S, Zhang J, Wang R, Luo X, Chen H,. The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung Cancer. 2010; 70: 63-70.
8. Friboulet L, Olaussen KA, Pignon J-P, et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med. 2013; 369: 1101-1110.
9. Bepler G, Williams C, Schell MJ, et al. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2013; 31: 2404-2412.
10. Niedernhofer LJ, Bhagwat N, Wood RD,. ERCC1 and non-small-cell lung cancer. N Engl J Med. 2007; 356: 2538-2540; author reply 2540-2541.
11. Bhagwat NR, Roginskaya VY, Acquafondata MB, Dhir R, Wood RD, Niedernhofer LJ,. Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue. Cancer Res. 2009; 69: 6831-6838.
12. Planchard D, Domont J, Taranchon E, et al. The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinoma. Ann Oncol. 2009; 20: 1257-1263.
13. Pierceall WE, Olaussen KA, Rousseau V, et al. Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses. Ann Oncol. 2012; 23: 2245-2252.
14. Hao D, Lau HY, Eliasziw M, et al. Comparing ERCC1 protein expression, mRNA levels, and genotype in squamous cell carcinomas of the head and neck treated with concurrent chemoradiation stratified by HPV status. Head Neck. 2012; 34: 785-791.
15. Vaezi A, Wang X, Buch S, et al. XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2011; 17: 5513-5522.
16. Duvvuri U, Shiwarski DJ, Xiao D, et al. TMEM16A induces MAPK and contributes directly to tumorigenesis and cancer progression. Cancer Res. 2012; 72: 3270-3281.
17. Li Z, Vance DE,. Phosphatidylcholine and choline homeostasis. J Lipid Res. 2008; 49: 1187-1194.
18. Wang Y, Sweitzer TD, Weinhold PA, Kent C,. Nuclear localization of soluble CTP:phosphocholine cytidylyltransferase. J Biol Chem. 1993; 268: 5899-5904.
19. Simon GR, Sharma S, Cantor A, Smith P, Bepler G,. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest. 2005; 127: 978-983.
20. Schoffski P, Taron M, Jimeno J, et al. Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study. Eur J Cancer. 2011; 47: 1006-1012.
21. Hoeijmakers JH,. DNA damage, aging, and cancer. N Engl J Med. 2009; 361: 1475-1485.
22. Lee KB, Parker RJ, Bohr V, Cornelison T, Reed E,. Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3. Carcinogenesis. 1993; 14: 2177-2180.
23. Ma D, Baruch D, Shu Y, et al. Using protein microarray technology to screen anti-ERCC1 monoclonal antibodies for specificity and applications in pathology. BMC Biotechnol. 2012; 12: 88.
24. Tronchere H, Record M, Terce F, Chap H,. Phosphatidylcholine cycle and regulation of phosphatidylcholine biosynthesis by enzyme translocation. Biochim Biophys Acta. 1994; 1212: 137-151.
25. Northwood IC, Tong AH, Crawford B, Drobnies AE, Cornell RB,. Shuttling of CTP:Phosphocholine cytidylyltransferase between the nucleus and endoplasmic reticulum accompanies the wave of phosphatidylcholine synthesis during the G→G transition. J Biol Chem. 1999; 274: 26240-26248.
26. Lagace TA, Ridgway ND,. The rate-limiting enzyme in phosphatidylcholine synthesis regulates proliferation of the nucleoplasmic reticulum. Mol Biol Cell. 2005; 16: 1120-1130.
27. Wang L, Magdaleno S, Tabas I, Jackowski S,. Early embryonic lethality in mice with targeted deletion of the CTP:phosphocholine cytidylyltransferase alpha gene (Pcyt1a). Mol Cell Biol. 2005; 25: 3357-3363.
28. Tian Y, Zhou R, Rehg JE, Jackowski S,. Role of phosphocholine cytidylyltransferase alpha in lung development. Mol Cell Biol. 2007; 27: 975-982.
29. Arsenault DJ, Yoo BH, Rosen KV, Ridgway ND,. ras-Induced up-regulation of CTP:phosphocholine cytidylyltransferase αcontributes to malignant transformation of intestinal epithelial cells. J Biol Chem. 2013; 288: 633-643.
30. Lagace TA, Ridgway ND,. Induction of apoptosis by lipophilic activators of CTP:phosphocholine cytidylyltransferase alpha (CCTalpha). Biochem J. 2005; 392 (pt 3): 449-456.
31. Fagone P, Gunter C, Sage CR, Gunn KE, Brewer JW, Jackowski S,. CTP:phosphocholine cytidylyltransferase alpha is required for B-cell proliferation and class switch recombination. J Biol Chem. 2009; 284: 6847-6854.
32. Linkous AG, Yazlovitskaya EM, Hallahan DE,. Cytosolic phospholipase A2 and lysophospholipids in tumor angiogenesis. J Natl Cancer Inst. 2010; 102: 1398-1412.
33. Kuner R, Muley T, Meister M, et al. Global gene expression analysis reveals specific patterns of cell junctions in non-small cell lung cancer subtypes. Lung Cancer. 2009; 63: 32-38.